Chronic obstructive pulmonary disease (COPD) is currently the third leading mortality cause in the world. There is neither a reliable blood biomarkers to confirm its diagnosis nor curative treatment. In this study we tested the hypothesis that the lung function and cerebrovascular responsiveness for COPD patients may be altered by a novel therapy through restoration of ANS homeostasis along with the improvement of clinical symptoms.
This abstract and the presentation materials are available to members only; a login is required.